Tel Aviv University announces $20m commercialisation fund with Tata Industries.

Kaiser Permanente Ventures and GE Asset Management are in the F round.

The money will be primarily used to support the planned commercial launch of the company's RhythmView WorkStation and FirMap Catheter in Europe and the US this year.

In 2011, Acumen reacquired ACU-193 and other assets from drugs peer Merck.

Gen9's previous investors include food maker Kraft Group, venture capital firms Draper Fisher Jurvetson and PBM Capital Group and angel investors, including Scott Schoen, former co-president of buyout firm Thomas H lee, and Weili Dai, co-founder of Marvell Technology Group.